Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
AbstractOBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.
Download data is not yet available.
How to Cite
Fagundes, R., Ferreira, L., & Pace, F. (2015). Health-Related Quality of Life in patients with hepatitis C in double and triple therapy . Revista Da Escola De Enfermagem Da USP, 49(6), 937-943. https://doi.org/10.1590/S0080-623420150000600009
Copyright (c) 2015 Revista da Escola de Enfermagem da USP
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.